來凱醫藥:LAE102取得積極初步結果
來凱醫藥-B(2105)公布,LAE102針對治療肥胖症在中國進行的I期多劑量遞增研究(「MAD研究」)取得積極初步結果,展現出令人鼓舞的增肌減脂趨勢。
Last Update:
29 9 月, 2025
Please share this article if you like it!
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.